Abstract
In summary, the Human Genome Project and the remarkable increase in our understanding of the molecular basis of atherosclerosis will lead to opportunities in translational research for the development of new molecular and genetic markers to identify patients at high risk for GAD who do not have manifestations of overt vascular disease. The Subclinical Cardiovascular Disease Study, which is being initiated by the U.S. National Heart, Lung, and Blood Institute, should provide valuable information for determining which genetic and molecular markers might be useful in conjunction with existing risk factors and noninvasive tests.
Get full access to this article
View all access options for this article.
